•Opus Genetics completes phase 3 enrollment for OPGx-LCA5 gene therapy•FDA clears Sight Sciences' OMNI Ultra Surgical System•Harrow adds TYRVAYA's global rights to dry eye portfolio•Atopic dermatitis linked to higher retinal detachment risk•OWL Leadership Summit 2026: key lessons on leading through change•Opus Genetics completes phase 3 enrollment for OPGx-LCA5 gene therapy•FDA clears Sight Sciences' OMNI Ultra Surgical System•Harrow adds TYRVAYA's global rights to dry eye portfolio•Atopic dermatitis linked to higher retinal detachment risk•OWL Leadership Summit 2026: key lessons on leading through change
HEADLINES
FEATURED
Federal agency also grants priority review for the once-daily oral therapeutic, establishing a PDUFA target action date for Feb. 12, 2027.
Earn FREE CE 24/7 with Courses by Eyes On Eyecare
Explore premium-quality, bite-sized courses featuring leading experts like Cecelia Koetting, OD, FAAO, and Cory Lappin, OD, MS, FAAO, and continuing education covering topics from ocular rosacea treatments to retinal disease.
